Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

NCT01203722 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: Fludarabine
DRUG: Cytoxan
RADIATION: Total Body Irradiation
PROCEDURE: Allogeneic Blood or Marrow Transplant
PROCEDURE: Peripheral Blood Stem Cell Transplant
DRUG: Mycophenolate Mofetil
DRUG: Sirolimus
DRUG: Tacrolimus

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

National Cancer Institute (NCI)